USPTO serial 79123060
TEIKOKU PHARMA
Reviewed by CopyMark Law Group
Reg. 4416497Status 739Registered
- Filing date
- Status date
- Registration date
- Oct 15, 2013
- Examiner
- MORRIS, KRISTINA KLOIBER
- Law office
- GENERIC WEB UPDATE
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with TEIKOKU PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
GB
San Jose, CA
San Jose, CA
San Jose, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bret E. Field
Bret E. Field Bozicevic, Field & Francis LLP201 Redwood Shores Parkway, Suite 200Redwood City, CA 94065United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | [ Cosmetics; cosmetic preparations; adhesives for cosmetic purposes; cosmetic masks; soaps for personal use; perfumery; essential oils; hair lotions ] | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceuticals for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; pharmaceutical preparations, compositions, creams and lotions for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations, namely, transdermal gel formulations, transdermal cream formulations, oral mucous formulations, transdermal patches, dressings and medical adhesive tapes for use in the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions | ACTIVE | — |
| 042 | Pharmaceutical research and development; pharmaceutical product evaluation, testing and inspection services; providing medical and scientific research information in the field of pharmaceuticals; information, advisory and consultancy services relating to all the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Teikoku Pharma UK Limited
- Other trademarks owned by Teikoku Pharma USA, Inc.
- Other trademarks owned by Teikoku Pharma USA, Inc.
- Other trademarks owned by Teikoku Pharma USA, Inc.
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named TEIKOKU PHARMA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 28, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 28, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 28, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 11, 2024 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| May 11, 2024 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| May 7, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Sep 15, 2023 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Oct 15, 2022 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Oct 6, 2022 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Oct 17, 2020 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Sep 5, 2020 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Aug 26, 2020 | INPC | INVALIDATION PROCESSED | — |
| Jul 21, 2020 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Nov 21, 2019 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Nov 21, 2019 | C75P | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Nov 21, 2019 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 14, 2019 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Oct 15, 2018 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jan 9, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 10, 2014 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 3, 2014 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 3, 2014 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 15, 2014 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 15, 2013 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 30, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 10, 2013 | NPUB | NOTICE OF PUBLICATION | — |
| Jun 24, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 17, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 30, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 30, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 22, 2013 | ALIE | ASSIGNED TO LIE | — |
| May 20, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 11, 2013 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Feb 27, 2013 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 28, 2013 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 28, 2013 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 26, 2013 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 25, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 18, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 15, 2013 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 9, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 3, 2013 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |